Valeant Pharmaceuticals targets buys in high-growth areas

May 02, 2013|Reuters

WINNIPEG, Manitoba, May 2 (Reuters) - ValeantPharmaceuticals International Inc ChiefExecutive Michael Pearson said on Thursday that the companywould focus on acquisitions with strong cash flow in high growthareas, avoiding western Europe and Japan, where bigpharmaceutical companies dominate.

A Valeant spokeswoman said the company would not comment onrecent deal speculation, which has involved U.S. genericdrugmaker Actavis Inc.